”It marks an essential step in our strategic efforts to determine main positions in anaphylaxis, meals allergy and different rising illness areas,” says ALK CEO on settlement with ARS Pharma.
发布者:BY JENS BETAK NIELSEN,转转请注明出处:https://robotalks.cn/alk-pays-ars-usd-145-million-upfront-for-nasal-spray-rights/